We are driven by the passion to nurture and preserve the precious moments of everyday life for all people, regardless of their health condition. From treatment to disease prevention, we will continue to develop innovative new drugs that contribute to better health and bring smiles to the faces of people everywhere.
Latest News
-
June 04, 2025
News Releases
Taiho Pharmaceutical and SyntheticGestalt Implements Technology Validation Towards Generative AI-Driven Expansion of Cysteinomix Drug Discovery Platform
-
June 02, 2025
News Releases
Taiho Pharmaceutical Out-Licenses LSD1 Inhibitor, TAS1440 to Benz Sciences
-
May 23, 2025
News Releases
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT Trial of Zipalertinib at ASCO 2025
-
May 23, 2025
News Releases
Results of Clinical Study of the Combination Regimen of
Decitabine and Cedazuridine Plus Venetoclax for Acute Myeloid Leukemia Announced at the American Society of Clinical Oncology Annual Meeting -
April 30, 2025
Information
Otsuka Holdings announces 1Q FY2025 financial results
MOVIE
TAIHO PHARMA STORY
Introducing Taiho Pharmaceutical’s history and its unique approaches in R&D.
This video is not intended to constitute promotion or advertisement of any products.